Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial
- PMID: 10208142
- DOI: 10.1001/jama.281.14.1275
Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial
Abstract
Context: Patients receiving dialysis commonly experience malnutrition, reduced muscle mass (sarcopenia), and fatigue for which no effective treatment has been identified. Anabolic steroids are known to increase muscle mass and strength in healthy individuals, but their effect on the sarcopenia and fatigue associated with long-term dialysis has not been evaluated.
Objective: To assess the effects of an anabolic steroid, nandrolone decanoate, on lean body mass (LBM), functional status, and quality of life in dialysis patients.
Design: Randomized, double-blind, placebo-controlled trial conducted between April 1996 and July 1997.
Setting: Hospital-based outpatient dialysis unit.
Patients: Twenty-nine patients undergoing dialysis for at least 3 months.
Intervention: Nandrolone decanoate, 100 mg (n = 14), or placebo (n = 15) by intramuscular injection once a week for 6 months.
Main outcome measures: Weight, LBM, fatigue, grip strength, walking and stair-climbing times, and treadmill performance after 3 and 6 months of treatment.
Results: Lean body mass increased significantly in patients given nandrolone compared with patients given placebo (mean change [SD], +4.5 [2.3] kg; P<.001 compared with baseline). This effect was significantly greater than the change in LBM in the placebo group (mean change [SD], +1.9 [1.6] kg; P = .003 compared with baseline; P = .005 compared with nandrolone group). Serum creatinine levels increased in the nandrolone group (+168 [203] mmol/L [1.9 [2.3] mg/dL]; P = .02) but not in the placebo group (-4.0 [177] mmol/L [0.04 [2.0] mg/dL]; P = .95), suggesting an increase in muscle mass. Time to complete the walking and stair-climbing test decreased from 36.5 to 32.7 seconds in the nandrolone group, while those in the placebo group increased from 38.7 to 42.1 seconds (P = .05). Peak oxygen consumption increased in the individuals in the nandrolone group who performed treadmill tests, but not to a statistically significant degree. Grip strength did not change in either group.
Conclusions: Treatment with nandrolone for 6 months resulted in a significant increase in LBM associated with functional improvement in patients undergoing dialysis.
Comment in
-
Is there a role for androgenic anabolic steroids in medical practice?JAMA. 1999 Apr 14;281(14):1326-7. doi: 10.1001/jama.281.14.1326. JAMA. 1999. PMID: 10208149 No abstract available.
Similar articles
-
Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: A randomized, controlled trial.J Am Soc Nephrol. 2006 Aug;17(8):2307-14. doi: 10.1681/ASN.2006010034. Epub 2006 Jul 6. J Am Soc Nephrol. 2006. PMID: 16825332 Clinical Trial.
-
Nutritional effect of nandrolone decanoate in predialysis patients with chronic kidney disease.J Ren Nutr. 2007 May;17(3):173-8. doi: 10.1053/j.jrn.2007.01.001. J Ren Nutr. 2007. PMID: 17462549 Clinical Trial.
-
A role for anabolic steroids in the rehabilitation of patients with COPD? A double-blind, placebo-controlled, randomized trial.Chest. 2003 Nov;124(5):1733-42. doi: 10.1378/chest.124.5.1733. Chest. 2003. PMID: 14605042 Clinical Trial.
-
Anabolic steroids in COPD: a review and preliminary results of a randomized trial.Chron Respir Dis. 2008;5(3):169-76. doi: 10.1177/1479972308092350. Chron Respir Dis. 2008. PMID: 18684793 Review.
-
Should androgenic anabolic steroids be considered in the treatment regime of selected chronic obstructive pulmonary disease patients?Curr Opin Pulm Med. 2012 Mar;18(2):118-24. doi: 10.1097/MCP.0b013e32834e9001. Curr Opin Pulm Med. 2012. PMID: 22189453 Review.
Cited by
-
Significance of 19-norandrosterone in athletes' urine samples.Br J Sports Med. 2006 Jul;40 Suppl 1(Suppl 1):i25-9. doi: 10.1136/bjsm.2006.028027. Br J Sports Med. 2006. PMID: 16799098 Free PMC article. Review.
-
An update on nutrition in chronic kidney disease.Int Urol Nephrol. 2007;39(1):239-46. doi: 10.1007/s11255-006-9108-3. Epub 2006 Nov 24. Int Urol Nephrol. 2007. PMID: 17476582 Review.
-
Nandrolone decanoate administration does not attenuate muscle atrophy during a short period of disuse.PLoS One. 2019 Jan 28;14(1):e0210823. doi: 10.1371/journal.pone.0210823. eCollection 2019. PLoS One. 2019. PMID: 30689637 Free PMC article.
-
Anabolic Steroid Use for Weight and Strength Gain in Critically Ill Patients: A Case Series and Review of the Literature.Case Rep Crit Care. 2018 May 7;2018:4545623. doi: 10.1155/2018/4545623. eCollection 2018. Case Rep Crit Care. 2018. PMID: 29854477 Free PMC article.
-
Sarcopenia in Chronic Kidney Disease: A Scoping Review of Prevalence, Risk Factors, Association with Outcomes, and Treatment.Calcif Tissue Int. 2022 Jan;110(1):1-31. doi: 10.1007/s00223-021-00898-1. Epub 2021 Aug 12. Calcif Tissue Int. 2022. PMID: 34383112 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous